Major Histocompatibility Complex Class II and Programmed Death Ligand 1 Expression Predict Outcome After Programmed Death 1 Blockade in Classic Hodgkin Lymphoma
| العنوان: | Major Histocompatibility Complex Class II and Programmed Death Ligand 1 Expression Predict Outcome After Programmed Death 1 Blockade in Classic Hodgkin Lymphoma |
|---|---|
| المؤلفون: | Pier Luigi Zinzani, Azra H. Ligon, Graham P. Collins, Anne Sumbul, Anas Younes, John M. Timmerman, Philippe Armand, Jan de Boer, Margaret A. Shipp, Stephanie Sasse, Robert A. Redd, Kerry J. Savage, John Kuruvilla, Jing Ouyang, Stephen M. Ansell, Jonathon B. Cohen, Sara Abdelrahman, Armando Santoro, Christine Pak, Donna Neuberg, Geraldine S. Pinkus, Scott J. Rodig, Kazunobu Kato, Michelle A. Fanale, Benedetto Farsaci, Radhakrishnan Ramchandren, Marek Trneny, Margaretha G.M. Roemer, Fathima Zumla Cader |
| المساهمون: | CCA - Imaging and biomarkers, Pathology, Roemer, Margaretha G M, Redd, Robert A, Cader, Fathima Zumla, Pak, Christine J, Abdelrahman, Sara, Ouyang, Jing, Sasse, Stephanie, Younes, Ana, Fanale, Michelle, Santoro, Armando, Zinzani, Pier Luigi, Timmerman, John, Collins, Graham P, Ramchandren, Radhakrishnan, Cohen, Jonathon B, De Boer, Jan Paul, Kuruvilla, John, Savage, Kerry J, Trneny, Marek, Ansell, Stephen, Kato, Kazunobu, Farsaci, Benedetto, Sumbul, Anne, Armand, Philippe, Neuberg, Donna S, Pinkus, Geraldine S, Ligon, Azra H, Rodig, Scott J, Shipp, Margaret A |
| المصدر: | Journal of Clinical Oncology, 36(10), 942-950. American Society of Clinical Oncology Roemer, M G M, Redd, R A, Cader, F Z, Pak, C J, Abdelrahman, S, Ouyang, J, Sasse, S, Younes, A, Fanale, M, Santoro, A, Zinzani, P L, Timmerman, J, Collins, G P, Ramchandren, R, Cohen, J B, de Boer, J P, Kuruvilla, J, Savage, K J, Trneny, M, Ansell, S, Kato, K, Farsaci, B, Sumbul, A, Armand, P, Neuberg, D S, Pinkus, G S, Ligon, A H, Rodig, S J & Shipp, M A 2018, ' Major histocompatibility complex class II and programmed death ligand 1 expression predict outcome after programmed death 1 blockade in classic Hodgkin lymphoma ', Journal of Clinical Oncology, vol. 36, no. 10, pp. 942-950 . https://doi.org/10.1200/JCO.2017.77.3994Test |
| بيانات النشر: | American Society of Clinical Oncology, 2018. |
| سنة النشر: | 2018 |
| مصطلحات موضوعية: | 0301 basic medicine, Cancer Research, Programmed Cell Death 1 Receptor, Antigen presentation, Major histocompatibility complex, B7-H1 Antigen, Cohort Studies, 03 medical and health sciences, Antineoplastic Agents, Immunological, 0302 clinical medicine, Predictive Value of Tests, MHC class I, Humans, Medicine, Reed-Sternberg Cells, Hodgkin Lymphoma, Hodgkin Reed-Sternberg, antitumor immunity, Antigen Presentation, MHC class II, biology, Beta-2 microglobulin, business.industry, Histocompatibility Antigens Class II, Hodgkin Disease, Progression-Free Survival, Transplantation, Nivolumab, Treatment Outcome, 030104 developmental biology, Oncology, 030220 oncology & carcinogenesis, Cancer research, biology.protein, Chromosomes, Human, Pair 9, beta 2-Microglobulin, business, Rapid Communication |
| الوصف: | Purpose Hodgkin Reed-Sternberg (HRS) cells evade antitumor immunity by multiple means, including gains of 9p24.1/ CD274(PD-L1)/ PDCD1LG2(PD-L2) and perturbed antigen presentation. Programmed death 1 (PD-1) receptor blockade is active in classic Hodgkin lymphoma (cHL) despite reported deficiencies of major histocompatibility complex (MHC) class I expression on HRS cells. Herein, we assess bases of sensitivity to PD-1 blockade in patients with relapsed/refractory cHL who were treated with nivolumab (anti–PD-1) in the CheckMate 205 trial. Methods HRS cells from archival tumor biopsies were evaluated for 9p24.1 alterations by fluorescence in situ hybridization and for expression of PD ligand 1 (PD-L1) and the antigen presentation pathway components—β2-microglobulin, MHC class I, and MHC class II—by immunohistochemistry. These parameters were correlated with clinical responses and progression-free survival (PFS) after PD-1 blockade. Results Patients with higher-level 9p24.1 copy gain and increased PD-L1 expression on HRS cells had superior PFS. HRS cell expression of β2-microglobulin/MHC class I was not predictive for complete remission or PFS after nivolumab therapy. In contrast, HRS cell expression of MHC class II was predictive for complete remission. In patients with a > 12-month interval between myeloablative autologous stem-cell transplantation and nivolumab therapy, HRS cell expression of MHC class II was associated with prolonged PFS. Conclusion Genetically driven PD-L1 expression and MHC class II positivity on HRS cells are potential predictors of favorable outcome after PD-1 blockade. In cHL, clinical responses to nivolumab were not dependent on HRS cell expression of MHC class I. |
| وصف الملف: | STAMPA |
| اللغة: | English |
| تدمد: | 0732-183X |
| الوصول الحر: | https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a355798180aa1cff5c684762541b9e63Test https://europepmc.org/articles/PMC5877802Test/ |
| حقوق: | OPEN |
| رقم الانضمام: | edsair.doi.dedup.....a355798180aa1cff5c684762541b9e63 |
| قاعدة البيانات: | OpenAIRE |
| تدمد: | 0732183X |
|---|